Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Leuk Lymphoma ; 57(2): 299-305, 2016 Feb.
Article in English | MEDLINE | ID: mdl-25976109

ABSTRACT

Post-transplant lymphoproliferative disorder (PTLD) is a rare, serious complication following solid organ transplantation, with an incidence of 2.6 cases per 1000 patient years. Optimal treatment strategies and risk stratifications specific to kidney transplantation are lacking and PTLD mortality remains high. This study investigated survival and prognosis in 89 cases of PTLD presenting over 44 years at Manchester Royal Infirmary. Patient survival following diagnosis was 72% at 6 months, 67% at 1 year and 54% at 3 years. In multivariate analysis, a poorer 3 year survival was associated with acute kidney injury at diagnosis (p = 0.0001), impaired renal function (p = 0.04), early onset (p = 0.02), T cell disease (p = 0.02) and previous treatment with anti-thymocyte globulin (p = 0.04). The inclusion of graft function adds prognostic value to risk stratification and should be explored further. Strategies to improve survival should include timing and choice of immuno-chemotherapy, preparation for dialysis and aggressive surveillance for sepsis and treatment toxicity.

2.
Pediatr Nephrol ; 30(10): 1861-71, 2015 Oct.
Article in English | MEDLINE | ID: mdl-25877916

ABSTRACT

BACKGROUND: Critically ill children and neonates are at high risk of developing acute kidney injury (AKI). AKI is associated with short- and long-term renal impairment and increased mortality. Current methods of diagnosing AKI rely on measurements of serum creatinine, which is a late and insensitive marker. Few studies to date have assessed AKI biomarkers in a heterogeneous patient cohort. METHODS: We conducted a prospective feasibility study in a paediatric intensive care setting over a 6-month period to describe the relationship between AKI (defined according to pRIFLE criteria) and new AKI biomarkers. RESULTS: In total, 49 patients between the ages of 16 days and 15 years were recruited for measurement of plasma cystatin C (Cys-C) and neutrophil gelatinase-associated lipocalin (pNGAL) concentrations, as well as for urinary kidney injury molecule-1 (KIM-1) and urinary NGAL (uNGAL) concentrations. Almost one-half (49 %) of the patient cohort experienced an AKI episode, and Cys-C and pNGAL were the strongest candidates for the detection of AKI. Our data suggest that the widely used estimated baseline creatinine clearance value of 120 mL/min/1.73 m(2) underestimates actual baseline function in patients admitted to paediatric intensive care units. CONCLUSIONS: This investigation demonstrates the feasibility of new AKI biomarker testing in a mixed patient cohort and provides novel biomarker profiling for further evaluation.


Subject(s)
Acute Kidney Injury/metabolism , Cystatin C/blood , Intensive Care Units, Pediatric , Lipocalins/blood , Membrane Glycoproteins/urine , Proto-Oncogene Proteins/blood , Acute Kidney Injury/diagnosis , Acute Kidney Injury/epidemiology , Acute-Phase Proteins , Adolescent , Biomarkers/blood , Biomarkers/urine , Child , Child, Preschool , Feasibility Studies , Female , Follow-Up Studies , Hepatitis A Virus Cellular Receptor 1 , Humans , Immunoassay , Incidence , Infant , Infant, Newborn , Lipocalin-2 , Male , Prognosis , Prospective Studies , Receptors, Virus , Survival Rate/trends , United Kingdom/epidemiology
3.
BMC Res Notes ; 8: 21, 2015 Feb 03.
Article in English | MEDLINE | ID: mdl-25643790

ABSTRACT

BACKGROUND: Extended criteria donor (ECD) and donation after circulatory death (DCD) kidneys are at increased risk of delayed graft function (DGF). Experimental evidence suggests that erythropoietin (EPO) attenuates renal damage in acute kidney injury. This study piloted the administration of high dose recombinant human EPO-beta at implantation of ECD and DCD kidneys, and evaluated biomarkers of kidney injury post-transplant. METHODS: Forty patients were randomly assigned to receive either rhEPO-b (100,000 iu) (n = 19 in the intervention group, as 1 patient was un-transplantable post randomisation), or placebo (n = 20) in this, double blind, placebo-controlled trial at Manchester Royal Infirmary from August 2007 to June 2009. Participants received either an ECD (n = 17) or DCD (n = 22) kidney. Adverse events, renal function, haematopoietic markers, and rejections were recorded out to 90 days post-transplant. Biomarkers of kidney injury (neutrophil gelatinase-associated lipocalin, Kidney Injury Molecule-1 and IL-18) were measured in blood and urine during the first post-operative week. RESULTS: The incidence of DGF (53% vs 55%) (RR = 1.0; CI = 0.5-1.6; p = 0.93) and slow graft function (SGF) (32% vs 25%) (RR = 1.1; CI = 0.5-1.9; p = 0.73) respectively, serum creatinine, eGFR, haemoglobin and haematocrit, blood pressure, and acute rejection were similar in the 2 study arms. High dose rhEPO-b had little effect on the temporal profiles of the biomarkers. CONCLUSIONS: High dose rhEPO-b appears to be safe and well tolerated in the early post- transplant period in this study, but has little effect on delayed or slow graft function in recipients of kidneys from DCD and ECD donors. Comparing the profiles of biomarkers of kidney injury (NGAL, IL-18 and KIM-1) showed little difference between the rhEPO-b treated and placebo groups. A meta-analysis of five trials yielded an overall estimate of the RR for DGF of 0.89 (CI = 0.73; 1.07), a modest effect favouring EPO but not a significant difference. A definitive trial based on this estimate would require 1000-2500 patients per arm for populations with base DGF rates of 50-30% and 90% power. Such a trial is clearly unfeasible. TRIAL REGISTRATION: EudraCT Number 2006-005373-22 ISRCTN ISRCTN85447324 registered 19/08/09.


Subject(s)
Delayed Graft Function/pathology , Erythropoietin/therapeutic use , Graft Rejection/pathology , Kidney Transplantation , Protective Agents/therapeutic use , Acute-Phase Proteins/urine , Aged , Biomarkers/blood , Biomarkers/urine , Creatinine/blood , Delayed Graft Function/blood , Delayed Graft Function/immunology , Delayed Graft Function/urine , Double-Blind Method , Female , Graft Rejection/blood , Graft Rejection/immunology , Graft Rejection/urine , Hepatitis A Virus Cellular Receptor 1 , Humans , Interleukin-18/blood , Interleukin-18/urine , Kidney/immunology , Kidney/metabolism , Kidney/pathology , Kidney/surgery , Kidney Function Tests , Lipocalin-2 , Lipocalins/blood , Lipocalins/urine , Male , Membrane Glycoproteins/blood , Membrane Glycoproteins/urine , Middle Aged , Pilot Projects , Proto-Oncogene Proteins/blood , Proto-Oncogene Proteins/urine , Receptors, Virus/blood , Tissue Donors
4.
Kidney Int ; 84(5): 980-8, 2013 Nov.
Article in English | MEDLINE | ID: mdl-23739231

ABSTRACT

The kidneys and the interstitial compartment play a vital role in body fluid regulation. The latter may be significantly altered in renal dysfunction, but experimental studies are lacking. To help define this we measured the subcutaneous interstitial pressure, bioimpedance volumes, and edema characteristics in 10 healthy subjects and 21 patients with obvious edema and chronic kidney disease (CKD). Interstitial edema was quantified by the time taken for a medial malleolar thumb pit to refill and termed the edema refill time. Interstitial pressure was significantly raised in CKD compared to healthy subjects. Total body water (TBW), extracellular fluid volume (ECFV), interstitial fluid volume, the ratio of the ECFV to the TBW, and segmental extracellular fluid volume were raised in CKD. The ratio of the ECFV to the TBW and the interstitial fluid volume were the best predictors of interstitial pressure. Significantly higher interstitial pressures were noted in edema of 2 weeks or less duration. A significant nonlinear relationship defined interstitial pressure and interstitial fluid volume. Edema refill time was significantly inversely related to interstitial pressure, interstitial compartment volumes, and edema vintage. Elevated interstitial pressure in CKD with obvious edema is a combined function of accumulated interstitial compartment fluid volumes, edema vintage, and tissue mechanical properties. The edema refill time may represent an important parameter in the clinical assessment of edema, providing additional information about interstitial pathophysiology in patients with CKD and fluid retention.


Subject(s)
Body Water/metabolism , Edema/etiology , Extracellular Fluid/metabolism , Fluid Shifts , Renal Insufficiency, Chronic/complications , Subcutaneous Tissue/metabolism , Water-Electrolyte Balance , Adult , Case-Control Studies , Edema/metabolism , Edema/physiopathology , Electric Impedance , Female , Humans , Male , Middle Aged , Models, Biological , Nonlinear Dynamics , Pressure , Renal Insufficiency, Chronic/metabolism , Renal Insufficiency, Chronic/physiopathology , Subcutaneous Tissue/physiopathology , Time Factors , Young Adult
5.
Transplantation ; 95(3): 470-8, 2013 Feb 15.
Article in English | MEDLINE | ID: mdl-23222821

ABSTRACT

BACKGROUND: There is little information in the literature describing the relationship between posttransplantation lymphoproliferative disorder (PTLD) incidence and presentation with both recipient Epstein-Barr virus (EBV) serostatus and EBV status of PTLD histology, particularly in the late posttransplantation period. METHODS: This study reports the largest UK single-center, single-organ analysis of PTLD to date in a retrospective cohort study of 80 cases occurring in 4189 adult renal transplant recipients. RESULTS: The incidence rate was 2.6 cases per 1000 patient-years (95% confidence interval [95% CI], 2.1-3.2) for PTLD, 1.8 (95% CI, 1.4-2.4) for non-Hodgkin's lymphoma, and 0.2 (95% CI, 0.07-4.2) for Hodgkin's lymphoma. Non-Hodgkin's lymphoma occurred at a rate 7.6 times that of the adult general population in England, whereas the rate for Hodgkin's lymphoma was 5.9 times. The incidence of PTLD was highest during the 10th to 14th posttransplantation years. Early-onset disease was associated with EBV-seronegative recipient status, EBV-positive histology, and the involvement of extranodal sites. PTLD occurring in EBV-seronegative recipients was associated with EBV nuclear antigen antibody deficiency, polymorphic disease, and the involvement of extranodal sites. EBV-negative histology occurred in 32% of cases at a median time to presentation of 109 months. PTLD involving the allograft, central nervous system, and skin was uncommon and occurred late. CONCLUSION: The incidence of PTLD is highest in the late posttransplantation period. Close clinical surveillance and education for transplant recipients is required for the duration of time while immunosuppressed. Failure to detect EBV DNA in blood should not reassure, particularly in patients with symptoms such as abdominal pain, oropharyngeal complaints, neck lumps, and B-symptoms.


Subject(s)
Epstein-Barr Virus Infections/epidemiology , Hodgkin Disease/epidemiology , Kidney Transplantation/adverse effects , Lymphoma, Non-Hodgkin/epidemiology , Lymphoproliferative Disorders/epidemiology , Transplantation , Adult , Aged , Antibodies, Viral/blood , Cohort Studies , Comorbidity , DNA, Viral/blood , Epstein-Barr Virus Infections/blood , Female , Herpesvirus 4, Human/genetics , Herpesvirus 4, Human/immunology , Hodgkin Disease/blood , Hodgkin Disease/mortality , Humans , Incidence , Kaplan-Meier Estimate , Kidney Transplantation/mortality , Lymphoma, Non-Hodgkin/blood , Lymphoma, Non-Hodgkin/mortality , Lymphoproliferative Disorders/blood , Lymphoproliferative Disorders/mortality , Male , Middle Aged , Postoperative Period , Retrospective Studies , Survival Rate , United Kingdom/epidemiology
6.
Blood Purif ; 32(2): 96-103, 2011.
Article in English | MEDLINE | ID: mdl-21372567

ABSTRACT

BACKGROUND: Uremic toxins are typically measured in plasma and little is known of their interstitial concentrations. We undertook experiments to validate a microdialysis technique for simultaneous recovery of small and large uremic toxins in the subcutaneous interstitial fluid (ISF). METHODS: Microdialysis catheters were inserted into the subcutaneous interstitium of 8 subjects (controls and uremic patients) and perfused using two different solutions at incremental flow rates to determine analyte recovery and ISF concentrations of urea and protein. RESULTS: 10% dextran-40 perfusate allowed the determination of interstitial concentrations of urea and protein reliably, by virtue of the exponential decay of their concentrations in the microdialysate with incremental flow rates (R(2) = 0.63-0.99). Interstitial and plasma urea correlated well (r = 0.95), as did interstitial urea from distant anatomical sites (r = 0.96). CONCLUSION: Cutaneous microdialysis with dextran-40 allows measurement of small and large molecule concentrations in ISF, creating an opportunity to characterize ISF in uremia.


Subject(s)
Extracellular Fluid/chemistry , Extracellular Space/chemistry , Microdialysis , Proteins/analysis , Renal Insufficiency, Chronic/metabolism , Subcutaneous Tissue/chemistry , Urea/analysis , Uremia/metabolism , Adult , Aged , Catheters , Dextrans/chemistry , Dialysis Solutions , Extracellular Fluid/metabolism , Extracellular Space/metabolism , Female , Humans , Infusion Pumps , Male , Microdialysis/instrumentation , Microdialysis/methods , Middle Aged , Plasma Substitutes/chemistry , Renal Insufficiency, Chronic/physiopathology , Subcutaneous Tissue/metabolism , Uremia/physiopathology
7.
J Nephrol ; 20(2): 177-85, 2007.
Article in English | MEDLINE | ID: mdl-17514622

ABSTRACT

BACKGROUND: Evidence from experimental models and clinical studies supports a major role for transforming growth factor-beta1 (TGF-beta1) in renal fibrosis. The aim of this study was to use repeated measurement of plasma TGF-beta1 as an indicator of persistent expression in a cohort of patients during the first 2 years post-renal transplantation and to correlate the findings with the development of chronic allograft nephropathy (CAN). METHODS: Active plasma TGF-beta1 was quantified in 100 consecutive renal allograft recipients (samples/patient = 35.6 +/- 12.9) under standard clinical management for a mean of 23 months (range 3.4-45 months). All patients were followed up for a minimum of 5 years. RESULTS: By 5 years, 23 patients had developed biopsy-proven CAN (CAN+), all of whom had been positive for plasma TGF-beta1. Demographic data were compared between patients who were CAN+ and CAN-negative (CAN-) and were not significantly different. TGF-beta1 exposure expressed as area under the curve / day (AUC/day) was correlated with the incidence of CAN. A Cox regression model was used to investigate the interrelationship of CAN, acute cellular rejection (ACR) and TGF-beta1 levels. ACR episodes were predictive of the development of CAN (log-rank test, p=0.003). After allowing for the effect of ACR (hazard ratio [HR]=3.6; 95% confidence ratio [95% CI], 1.5-8.7) between patients with and without ACR episodes, p=0.003), the independent effect of TGF-beta1 was confirmed (HR=1.7; 95% CI, 1.1-2.6; per quartile; p=0.008). CONCLUSION: The results demonstrate that episodes of ACR are highly predictive of chronic damage in the graft. Cumulative exposure to TGF-beta1 is identified as an independent predictor of CAN in the first 2 years posttransplantation.


Subject(s)
Kidney Diseases/etiology , Kidney Transplantation/adverse effects , Transforming Growth Factor beta1/metabolism , Acute Disease , Adult , Chronic Disease , Cohort Studies , Female , Graft Rejection/complications , Humans , Male , Middle Aged , Proportional Hazards Models , Prospective Studies , Transplantation, Homologous
8.
Arthritis Res Ther ; 8(3): R81, 2006.
Article in English | MEDLINE | ID: mdl-16646981

ABSTRACT

The efficiency of activating latent transforming growth factor (TGF)-beta1 in systemic lupus erythematosus (SLE) may control the balance between inflammation and fibrosis, modulating the disease phenotype. To test this hypothesis we studied the ability to activate TGF-beta1 in SLE patients and control individuals within the context of inflammatory disease activity, cumulative organ damage and early atherosclerosis. An Activation Index (AI) for TGF-beta1 was determined for 32 patients with SLE and 33 age-matched and sex-matched control individuals by quantifying the increase in active TGF-beta1 under controlled standard conditions. Apoptosis in peripheral blood mononuclear cells was determined by fluorescence-activated cell sorting. Carotid artery intima-media thickness was measured using standard Doppler ultrasound. These measures were compared between patients and control individuals. In an analysis conducted in patients, we assessed the associations of these measures with SLE phenotype, including early atherosclerosis. Both intima-media thickness and TGF-beta1 AI for SLE patients were within the normal range. There was a significant inverse association between TGF-beta1 AI and levels of apoptosis in peripheral blood mononuclear cells after 24 hours in culture for both SLE patients and control individuals. Only in SLE patients was there a significant negative correlation between TGF-beta1 AI and low-density lipoprotein cholesterol (r = -0.404; P = 0.022) and between TGF-beta1 AI and carotid artery intima-media thickness (r = -0.587; P = 0.0004). A low AI was associated with irreversible damage (SLICC [Systemic Lupus International Collaborating Clinics] Damage Index > or = 1) and was inversely correlated with disease duration. Intima-media thickness was significantly linked to total cholesterol (r = 0.371; P = 0.037). To conclude, in SLE low normal TGF-beta1 activation was linked with increased lymphocyte apoptosis, irreversible organ damage, disease duration, calculated low-density lipoprotein levels and increased carotid IMT, and may contribute to the development of early atherosclerosis.


Subject(s)
Atherosclerosis/blood , Lupus Erythematosus, Systemic/blood , Transforming Growth Factor beta/blood , Apoptosis , Atherosclerosis/pathology , Cholesterol, LDL/blood , England , Female , Humans , Lupus Erythematosus, Systemic/pathology , Lymphocytes/immunology , Lymphocytes/pathology , Male , Reference Values , Transforming Growth Factor beta1 , Tunica Media/pathology , White People
9.
Nephrol Dial Transplant ; 20(11): 2427-32, 2005 Nov.
Article in English | MEDLINE | ID: mdl-16046504

ABSTRACT

BACKGROUND: Changes in renal vasculature, with vascular and interstitial fibrosis, are hallmarks of progression to chronic kidney disease (CKD) stage 5. Vascular endothelial growth factor (VEGF) is a potent angiogenic and vascular permeability factor. Transforming growth factor-beta1 (TGF-beta1) plays a critical role in promoting extracellular matrix (ECM) deposition and fibrosis. This study investigates whether genetic polymorphisms of VEGF or TGF-beta1 are associated with (i) progressive decline in renal function in patients with glomerular disorders (cohort 1) and (ii) predisposition to CKD stage 5 in a separate group of renal transplant recipients with various primary diseases (cohort 2). METHODS: Two patient groups were studied. Cohort 1 comprised 91 patients with biopsy-proven glomerular disease who were followed-up for 5 years before categorization as either non-progressors (with stable serum creatinine or < or =30% increase over 5 years, n = 39) or progressors (requiring dialysis, transplantation or whose serum creatinine increased by >30% over 5 years, n = 52). Cohort 2 comprised 107 patients with various primary renal diseases, who had reached CKD stage 5 and undergone renal transplantation at the time of study. All patients were genotyped for the VEGF polymorphisms at positions -460 (C/T) and +405 (G/C). Linkage disequilibrium (LD) was established using EHplus. SNPHAP was used to estimate haplotype frequency and to infer haplotypes to all patients. Cohort 1 patients were genotyped for the TGF-beta1 polymorphisms at positions -800, -509, codons 10 and 25. Genotyping was performed by polymerase chain reaction-restriction length polymorphism (PCR-RFLP). RESULTS: In cohort 1, there was a significant increase in frequency of the -460 VEGF CC genotype 30.8 vs 5.1%, P = 0.008; odds ratio (OR), CC vs TT 10.67, 95% confidence interval (CI), 1.94-58.72 and C allele 56.7 vs 37.2%, P = 0.009; OR 2.22, 95% CI, 1.21-4.04, in the progressor patients when compared with the non-progressors. In cohort 2, there was a significant increase in the VEGF -460 CC genotype when compared with healthy volunteers 37 vs 20.8%, P = 0.011; OR CC vs TT 1.59, 95% CI, 0.72-3.51. The -460 and +405 polymorphisms were in LD P < 0.00007. There were significant differences in diplotype (haplotype pair) frequencies in cohort 1 and 2, P = 0.018, which confirmed the importance of the -460C allele. There were no associations between the VEGF +405 or TGF-beta1 polymorphisms and progressive renal disease. CONCLUSION: In this study, we have demonstrated an association between the VEGF -460 polymorphism and progression to CKD stage 5. The function of this polymorphism remains unclear although previous evidence suggests that promoter constructs containing this single nucleotide polymorphism (SNP) have been associated with increased activity. Clearly there is a role for TGF-beta1 in chronic kidney disease. However, this study found no associations with four TGF-beta1 polymorphisms in this cohort.


Subject(s)
DNA/genetics , Kidney Failure, Chronic/genetics , Vascular Endothelial Growth Factors/genetics , Biopsy , Disease Progression , Female , Follow-Up Studies , Genetic Markers , Genotype , Humans , Kidney Failure, Chronic/blood , Kidney Failure, Chronic/pathology , Linkage Disequilibrium , Male , Middle Aged , Polymerase Chain Reaction , Polymorphism, Restriction Fragment Length , Severity of Illness Index , Transforming Growth Factor beta/genetics , Transforming Growth Factor beta1
SELECTION OF CITATIONS
SEARCH DETAIL
...